A citation-based method for searching scientific literature

Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad, John N Staffurth, Paul Mainwaring, Stephen Harland, Thomas W Flaig, Thomas E Hutson, Tina Cheng, Helen Patterson, John D Hainsworth, Charles J Ryan, Cora N Sternberg, Susan L Ellard, Aude Fléchon, Mansoor Saleh, Mark Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M Haqq, Howard I Scher. N Engl J Med 2011
Times Cited: 2962







List of co-cited articles
478 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
76

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
43

Abiraterone in metastatic prostate cancer without previous chemotherapy.
Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng,[...]. N Engl J Med 2013
40

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. N Engl J Med 2017
992
27

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
27

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Ian F Tannock, Ronald de Wit, William R Berry, Jozsef Horti, Anna Pluzanska, Kim N Chi, Stephane Oudard, Christine Théodore, Nicholas D James, Ingela Turesson,[...]. N Engl J Med 2004
27

Alpha emitter radium-223 and survival in metastatic prostate cancer.
C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, S D Fosså, A Chodacki, P Wiechno, J Logue, M Seke,[...]. N Engl J Med 2013
24

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A Hadaschik, Julie N Graff, David Olmos, Paul N Mainwaring, Ji Youl Lee, Hiroji Uemura,[...]. N Engl J Med 2018
580
23

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D Shore,[...]. J Clin Oncol 2019
281
22

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss,[...]. N Engl J Med 2019
340
21

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, Ubirajara Ferreira, Petro Ivashchenko, Eren Demirhan, Katharina Modelska, De Phung,[...]. N Engl J Med 2018
482
21

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Ian D Davis, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath,[...]. N Engl J Med 2019
464
21

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Alastair W S Ritchie, Claire L Amos, Clare Gilson, Rob J Jones,[...]. N Engl J Med 2017
842
19

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Kim N Chi, Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Robert Given, Álvaro Juárez Soto, Axel S Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura,[...]. N Engl J Med 2019
433
19

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Charles J Ryan, Matthew R Smith, Karim Fizazi, Fred Saad, Peter F A Mulders, Cora N Sternberg, Kurt Miller, Christopher J Logothetis, Neal D Shore, Eric J Small,[...]. Lancet Oncol 2015
784
17

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
517
16

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
15

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard,[...]. Lancet 2016
15

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
14

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Howard I Scher, Susan Halabi, Ian Tannock, Michael Morris, Cora N Sternberg, Michael A Carducci, Mario A Eisenberger, Celestia Higano, Glenn J Bubley, Robert Dreicer,[...]. J Clin Oncol 2008
14

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Daniel P Petrylak, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Jeffrey A Jones, Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli,[...]. N Engl J Med 2004
13

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Chris Tran, Samedy Ouk, Nicola J Clegg, Yu Chen, Philip A Watson, Vivek Arora, John Wongvipat, Peter M Smith-Jones, Dongwon Yoo, Andrew Kwon,[...]. Science 2009
13

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. Lancet Oncol 2019
206
13

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
12

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor,[...]. N Engl J Med 2014
12

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Karim Fizazi, Howard I Scher, Arturo Molina, Christopher J Logothetis, Kim N Chi, Robert J Jones, John N Staffurth, Scott North, Nicholas J Vogelzang, Fred Saad,[...]. Lancet Oncol 2012
896
11

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Ronald de Wit, Johann de Bono, Cora N Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles,[...]. N Engl J Med 2019
206
10

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
660
9

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
9

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Philip Cornford, Joaquim Bellmunt, Michel Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason,[...]. Eur Urol 2017
901
9

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, Glenn Liu, David F Jarrard, Noah M Hahn, Daniel H Shevrin, Robert Dreicer, Maha Hussain, Mario Eisenberger,[...]. J Clin Oncol 2018
344
9

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
9

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Cora N Sternberg, Karim Fizazi, Fred Saad, Neal D Shore, Ugo De Giorgi, David F Penson, Ubirajara Ferreira, Eleni Efstathiou, Katarzyna Madziarska, Michael P Kolinsky,[...]. N Engl J Med 2020
100
8

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss,[...]. N Engl J Med 2020
70
11

Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Marcin Cieslik, Matteo Benelli, Dan Robinson, Eliezer M Van Allen,[...]. Proc Natl Acad Sci U S A 2019
380
8

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gwenaelle Gravis, Karim Fizazi, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre,[...]. Lancet Oncol 2013
403
8

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Dominik R Berthold, Gregory R Pond, Freidele Soban, Ronald de Wit, Mario Eisenberger, Ian F Tannock. J Clin Oncol 2008
776
8

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
8

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
8

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja, Joanna Vergidis, Muhammad Zulfiqar, Katherine Sunderland, Arun A Azad, Christian K Kollmannsberger,[...]. Lancet Oncol 2019
127
8

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Gerhardt Attard, Alison H M Reid, Timothy A Yap, Florence Raynaud, Mitch Dowsett, Sarah Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd,[...]. J Clin Oncol 2008
664
7

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Neal D Shore, Fred Saad, Michael S Cookson, Daniel J George, Daniel R Saltzstein, Ronald Tutrone, Hideyuki Akaza, Alberto Bossi, David F van Veenhuyzen, Bryan Selby,[...]. N Engl J Med 2020
107
7


Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Philip A Watson, Vivek K Arora, Charles L Sawyers. Nat Rev Cancer 2015
653
7

Epidemiology of Prostate Cancer.
Prashanth Rawla. World J Oncol 2019
545
7

Metastatic Prostate Cancer.
Oliver Sartor, Johann S de Bono. N Engl J Med 2018
212
7

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Stéphane Oudard, Karim Fizazi, Lisa Sengeløv, Gedske Daugaard, Fred Saad, Steinbjørn Hansen, Marie Hjälm-Eriksson, Jacek Jassem, Antoine Thiery-Vuillemin, Orazio Caffo,[...]. J Clin Oncol 2017
160
6

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Nancy L Keating, A James O'Malley, Matthew R Smith. J Clin Oncol 2006
6

ARN-509: a novel antiandrogen for prostate cancer treatment.
Nicola J Clegg, John Wongvipat, James D Joseph, Chris Tran, Samedy Ouk, Anna Dilhas, Yu Chen, Kate Grillot, Eric D Bischoff, Ling Cai,[...]. Cancer Res 2012
412
6

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Arun A Azad, Stanislav V Volik, Alexander W Wyatt, Anne Haegert, Stephane Le Bihan, Robert H Bell, Shawn A Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov,[...]. Clin Cancer Res 2015
317
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.